Detalles de la búsqueda
1.
Effect of ASP2205 fumarate, a novel 5-HT2C receptor agonist, on urethral closure function in rats.
J Pharmacol Sci
; 139(4): 333-339, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30871873
2.
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Biol Pharm Bull
; 42(3): 507-511, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30828082
3.
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
J Pharmacol Sci
; 131(3): 198-208, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27430987
4.
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
J Pharmacol Sci
; 130(3): 159-69, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26970780
5.
Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor.
Endocr Res
; 38(3): 168-183, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23374077
6.
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
J Pharmacol Sci
; 120(1): 36-44, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22971845
7.
Urethral function and histopathology in aged female rats as a stress urinary incontinence model.
Low Urin Tract Symptoms
; 11(2): O186-O192, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29266769
8.
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Eur J Pharmacol
; 818: 545-553, 2018 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29154936
9.
Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
Eur J Pharmacol
; 809: 163-171, 2017 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28506912
10.
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
Biochem Pharmacol
; 72(1): 42-52, 2006 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-16696951
11.
Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Arch Pharm Res
; 39(2): 259-270, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26450351
12.
Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG.
Pharmacol Res Perspect
; 4(4): e00244, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28116097
13.
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
J Pharm Pharmacol
; 66(7): 975-87, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24533859
14.
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Eur J Pharmacol
; 727: 66-74, 2014 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24486393
15.
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Eur J Pharmacol
; 715(1-3): 246-55, 2013 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23707905
16.
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Naunyn Schmiedebergs Arch Pharmacol
; 385(4): 423-36, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22139434
Resultados
1 -
16
de 16
1
Próxima >
>>